Top 4 NYSE Stocks In The Biotechnology Industry With The Highest Revenue Estimates
Below are the top biotechnology stocks on the NYSE in terms of revenue estimate for the current year.
Analysts expect Charles River Laboratories International (NYSE: CRL) to post revenue of $1.14 billion for the year ending December, 2012. Charles River Laboratories' trailing-twelve-month ROE is 17.83%.
Emergent BioSolutions (NYSE: EBS) is expected to report revenue of $286.38 million for the year ending December, 2012. Emergent BioSolutions' PEG ratio is 0.72.
Cambrex (NYSE: CBM) is likely to post revenue of $274.60 million in the year ending December, 2012. Cambrex's trailing-twelve-month operating margin is 12.83%.
ShangPharma (NYSE: SHP) may report revenue of $132.94 million in the year ending December, 2012. ShangPharma had $34.74 million in total cash for the recent quarter.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.